QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 arcutis-biotherapeutics-publshes-long-term-safety-and-efficacy-data-of-zoryve-foam-03-in-individuals-with-seborrheic-dermatitis-in-american-journal-of-clinical-dermatology

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seb...

 goldman-sachs-maintains-neutral-on-arcutis-biotherapeutics-raises-price-target-to-29

Goldman Sachs analyst Richard Law maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral and raises the price targe...

 arcutis-biotherapeutics-announces-commercial-roll-out-of-zoryve-cream-to-treat-mild-to-moderate-atopic-dermatitis-in-children-ages-2-to-5-in-us

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inno...

 arcutis-biotherapeutics-q3-eps-006-beats-010-estimate-sales-99219m-beat-86978m-estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate ...

 arcutis-submits-snda-to-expand-zoryve-cream-use-for-plaque-psoriasis-in-children-as-young-as-2

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as youn...

 top-5-biotech-stocks-with-strong-momentum

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

 needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-22

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

 arcutis-biotherapeutics-q2-eps-013-beats-017-estimate-sales-81504m-beat-72753m-estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate ...

 goldman-sachs-initiates-coverage-on-arcutis-biotherapeutics-with-neutral-rating-announces-price-target-of-18

Goldman Sachs analyst Richard Law initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral rating and ann...

 arcutis-biotherapeutics-zoryve-cream-015-received-recommendation-in-focused-guideline-update-for-management-of-adult-ad-from-aad

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION